Trevena (TRVN) Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. More details

TRVN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($11K)

Latest financial reports are more than a year old

Shares are highly illiquid

TRVN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Trevena, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Trevena
Historical stock prices
Current Share Price	US$0.011
52 Week High	US$1.27
52 Week Low	US$0.001
Beta	0
1 Month Change	-44.50%
3 Month Change	0%
1 Year Change	-99.10%
3 Year Change	-99.90%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Aug 10

Trevena Q2 2022 Earnings Preview

Trevena (NASDAQ:TRVN) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (-11.1% Y/Y) and the consensus Revenue Estimate is $0.31M (+72.2% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 0 upward revisions and 3 downward.

Seeking Alpha • Jul 29

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) shares dropped 5% on Friday pre-market after the biopharmaceutical company announced preferred stock offering. The offering consists of 1,800 shares of Series A convertible preferred stock, 200 shares of Series B convertible preferred stock and warrants to purchase up to 8M shares of common stock. Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share. They are convertible into an aggregate of 8M shares of common stock. The warrants will be exercisable at $0.263/share, beginning on the later of six months following the date of issuance and the effective date of a reverse stock split of the company’s common stock in an amount sufficient to permit the exercise in full of the warrants. They will expire five and one-half years following the date of issuance. Offering is expected to close on or about July 29, 2022. Total gross proceeds will be $2M; net proceeds will be used for general corporate purposes.

Analysis Article • Jul 08

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Mar 19

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Dec 14

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena continues to struggle to get OLINVYK off the launch pad. COVID-19 headwinds are persisting, and it is having an impact on the company's ability to get through P&T committees. Trevena is building a body of evidence in OLINVYK's post-approval program. The company expects these additional studies should improve product adoption and potentially expand OLINVYK's label. The market has crushed the share price under anemic volume. Now, TRVN's market cap is struggling to stay above $100M. I believe TRVN offers a great risk-reward at these prices. My "house money" position has gone from comfortably green, to a deep dark red. I am looking to change my strategy to claw my way back into green.

Seeking Alpha • Aug 17

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena recently reported disappointing Q2 earnings that revealed they completely missed the Street's expectations and only pulled in ~$180K in revenue. The COVID-19 headwinds are slamming Trevena and the forecast does not appear to be clearing up. As a result, I believe investors need to be patient with TRVN. Despite the underwhelming earnings, the company reported some encouraging commercial trends that could bode well for the second half of 2021 and potentially establish some momentum in 2022. I discuss why I am remaining patient with my TRVN and how I intend to manage this position as the world continues to deal with the ongoing pandemic.

Shareholder Returns

	TRVN	US Biotechs	US Market
7D	0%	-0.5%	0.5%
1Y	-99.1%	44.4%	25.4%

Return vs Industry: TRVN underperformed the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: TRVN underperformed the US Market which returned 25.4% over the past year.

Price Volatility

Is TRVN's price volatile compared to industry and market?
TRVN volatility
TRVN Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.0%
10% least volatile stocks in US Market	3.2%

Stable Share Price: TRVN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine TRVN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	n/a	Carrie Bourdow	www.trevena.com

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena, Inc. Fundamentals Summary

How do Trevena's earnings and revenue compare to its market cap?
TRVN fundamental statistics
Market cap	US$10.64k
Earnings (TTM)	-US$34.04m
Revenue (TTM)	US$546.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is TRVN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRVN income statement (TTM)
Revenue	US$546.00k
Cost of Revenue	US$1.59m
Gross Profit	-US$1.04m
Other Expenses	US$33.00m
Earnings	-US$34.04m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did TRVN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/14 23:10
End of Day Share Price	2026/05/08 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Trevena, Inc. is covered by 13 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ying Huang	Barclays
Ritu Baral	Canaccord Genuity
Brandon Folkes	Cantor Fitzgerald & Co.

Trevena (TRVN) Stock Overview

Risk Analysis

Trevena, Inc. Competitors

Vincerx Pharma

Synairgen

Aditxt

Lipella Pharmaceuticals

Price History & Performance

Recent News & Updates

Trevena, Inc. announced delayed annual 10-K filing

Trevena, Inc. Appoints Katrine Sutton as Principal Financial Officer and Principal Accounting Officer

Trevena, Inc.(OTCPK:TRVN) dropped from S&P TMI Index

Trevena, Inc.(OTCPK:TRVN) dropped from NASDAQ Composite Index

Trevena Announces Receipt of Nasdaq Delisting Notification

Trevena Regains Compliance with the Minimum Bid Price Requirement from Nasdaq

Recent updates

Trevena, Inc. announced delayed annual 10-K filing

Trevena, Inc. Appoints Katrine Sutton as Principal Financial Officer and Principal Accounting Officer

Trevena, Inc.(OTCPK:TRVN) dropped from S&P TMI Index

Trevena, Inc.(OTCPK:TRVN) dropped from NASDAQ Composite Index

Trevena Announces Receipt of Nasdaq Delisting Notification

Trevena Regains Compliance with the Minimum Bid Price Requirement from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.69 loss in 2Q 2023)

Trevena, Inc. Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.81 loss in 1Q 2023)

Nasdaq Hearings Panel Grants Trevena an Extension Until August 28, 2024 to Regain Compliance with the Nasdaq Continued Listing Requirements, Including the Minimum Bid Price Requirement and Equity Standard Requirement

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Price target decreased to US$28.67

Insufficient new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Consensus forecasts updated

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Shareholder Returns

Price Volatility

About the Company

Trevena, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics